DLRC Regulatory Consultancy published an article exploring the implications of the proposed EU Pharmaceutical Reform for industry and how ePI may transform medicines information creation, management, and access.

Bringing your product to market is complex; DLRC helps simplify the journey. Operating from our UK, Germany and US offices, we partner globally with life science developers of all sizes, from early-stage start-ups and SMEs to top five global pharmaceutical companies. Our senior-led teams develop and deliver phase-appropriate strategies across regulatory affairs, HTA and market access, supporting products from non-clinical development through to post-approval and lifecycle management. We combine deep regulatory expertise with practical HTA and market access insight, helping companies plan evidence generation, engage confidently with regulators and payers and make informed decisions that support timely patient access. Our consultants are experienced specialists in non-clinical, CMC, clinical development, MedTech, HTA and market access, with backgrounds in industry, health authorities, and assessment agencies. Our commitment to quality and regulatory excellence has been recognised through multiple industry and business awards and accreditations, including the Queen’s and King’s Awards for Enterprise in International Trade, TOPRA Awards for Regulatory Excellence, ISO 9001 accreditation, Investors in People Silver and Cyber Essentials. We are a Certified B Corporation™, reflecting our commitment to high standards of social, environmental and governance performance. DLRC also has Science Based Targets initiative (SBTi) validated targets, confirming that our climate goals are aligned with recognised, science‑based emissions reduction pathways. We work with Planet Mark to calculate and monitor our carbon emissions, supporting our ongoing environmental commitments. Speak to us to find out how our integrated regulatory, HTA and market access expertise can support your organisation and help bring innovative products to patients sooner.